← Oncology Approval Tracker

FDA DECISION ·

Gavreto

pralsetinib · Blueprint Medicines

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Aug 9, 2023

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with metastatic non-small cell lung cancer with a RET gene fusion identified by an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

Added a second selective RET inhibitor option for metastatic lung cancer under accelerated approval.

What research teams should watch

Document the fusion result, prior treatment exposure and monitoring for blood-pressure changes and pneumonitis.

PRIMARY RECORDS

Sources